此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

CT-95 在晚期癌症中与间皮素表达相关

2026年11月3日 更新者:Context Therapeutics Inc.

CT-95 在晚期癌症中与间皮素表达相关的 1 期研究

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.

研究概览

详细说明

Phase 1a Dose Escalation: Participants with ovarian epithelial tumors, primary peritoneal or fallopian tube cancer (PROC), epithelioid mesothelioma, lung adenocarcinoma, pancreatic adenocarcinoma, colorectal cancer, cholangiocarcinoma, and gastric/GEJ adenocarcinomas will be enrolled in one of approximately 9 dose escalation cohorts to assess the safety and tolerability of CT-95, as well as determine the maximum tolerated dose (MTD) or other recommended dose(s) for expansion (RDE[s]) for further dose expansion cohorts.

Participants will receive CT-95 as a single agent administered once weekly (QW) intravenously (IV) over a 4-week cycle.

Phase 1b Dose Expansion: The RDE(s) of CT-95 determined in Phase 1a will be evaluated in 2-4 indication-specific expansion cohorts of up to 20 subjects each (i.e. up to 80 participants total). Different indications, dose levels, and/or schedules may be explored. The expansion doses and/or dosing schedules for Phase 1b will be determined by Sponsor in conjunction with SRC based upon all available safety, PK, PD, biomarker, and preliminary efficacy data from Phase 1a.

研究类型

介入性

注册 (实际的)

19

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Colorado
      • Denver、Colorado、美国、80218
        • Context Investigational Site
    • Illinois
      • Chicago、Illinois、美国、60637
        • Context Investigational Site
    • Michigan
      • Grand Rapids、Michigan、美国、49546
        • Context Investigational Site
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • Context Investigational Site
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • University of Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Context Investigational Site
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • Context Investigational Site
    • Texas
      • San Antonio、Texas、美国、78229
        • Context Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • ECOG 0 or 1
  • Subjects with evaluable disease per RECIST 1.1 or mRECIST
  • Subjects with adequate organ function.
  • Subjects with advanced cancers associated with mesothelin expression

Exclusion Criteria:

  • Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.
  • Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy
  • Concurrent participation in another investigational clinical trial.
  • Evidence of leptomeningeal disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:CT-95

Phase 1a: Dose Escalation - each dose cohort will assess toxicity 28 days following the first dose of CT95 anticipate a total of 8 dose cohorts.

Phase 1b: Dose Expansion - approximately 80 participants will be evaluated in 2-4 indication-specific expansion cohorts.

MSLN bispecific antibody to be administered according to the dose and schedule of the assigned cohort until documentation of disease progression (or confirmed disease progression), unacceptable toxicity, or participant/physician decision.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Determine the MTD or RD of CT-95 [Safety and Tolerability]
大体时间:From date of first dose of CT-95 until 28 days following the first dose.

The frequency of dose-limiting toxicities (DLTs) will be analyzed along with safety and tolerability measures to determine the MTD or RD of CT-95.

From date of first dose of CT-95 until 28 days following the first dose.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
大体时间:From date of first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.

The frequency and severity of adverse events, serious adverse events, and adverse events of special interest will be analyzed.

From date of first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.

次要结果测量

结果测量
措施说明
大体时间
Evaluate Response Rates [Anti-tumor Activity]
大体时间:At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first

Overall response rates will be calculated using RECIST 1.1 (and mRECIST for patients with mesothelioma) for CT-95.

At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first
Evaluate Progression-free Survival [Anti-tumor Activity]
大体时间:At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.

PFS will be summarized using RECIST 1.1 (and mRECIST for patients with mesothelioma) for CT-95.

At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.
Evaluate Overall Survival [Survival]
大体时间:From the time of the first dose of CT-95 until approximately two years post-first dose.

Overall survival will be summarized for CT-95.

From the time of the first dose of CT-95 until approximately two years post-first dose.
Evaluate the Maximum Serum Concentration (Cmax) [Pharmacokinetics]
大体时间:From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.

Serum concentrations of CT-95 analyzed as a function of time relative to dosing will be calculated.

From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.
Evaluate the Area Under the Curve (AUC) [Pharmacokinetics]
大体时间:From date of first dose of CT-95 for 5 months or treatment discontinuation, whichever comes first.

The AUC of CT-95 analyzed as a function of time relative to dosing will be calculated.

From date of first dose of CT-95 for 5 months or treatment discontinuation, whichever comes first.
Evaluate Anti-Drug Antibodies [Immunogenicity]
大体时间:From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.

Incidence and titer of ADAs will be evaluated.

From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Karen Chagin, MD、Context Therapeutics Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年3月31日

初级完成 (实际的)

2026年10月9日

研究完成 (实际的)

2026年10月9日

研究注册日期

首次提交

2024年12月18日

首先提交符合 QC 标准的

2024年12月24日

首次发布 (实际的)

2025年1月1日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅